Related Experiment Video
Updated: Apr 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Severe, but manageable hypoxia caused by bronchospasm induced by bevacizumab
Hirokazu Taniguchi1, Tomoko Tsuchida2, Yoichi Nakamura2
1Second Department of Internal Medicine, Nagasaki University School of Medicine Nagasaki, Japan ; Sasebo City General Hospital Sasebo, Japan.
Abstract:
Bevacizumab has a lower risk of treatment-related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year-old man with lung adenocarcinoma and childhood asthma. Then, grade 3 hypoxia developed and improved spontaneously. This reversible obstructive lung disorder was confirmed using a flow-volume loop, and the patient was diagnosed as having a bronchospasm due to infusion reaction of bevacizumab. This bronchospasm was easily manageable and preventable using an oral bronchodilator and an inhalant combination product, and the patient continued with bevacizumab therapy until the disease progression.
Related Concept Videos
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Hyperpnea and Hyperventilation
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

